enzalutamide,olaparib,darolutamide,abiraterone,Apalutamide
bayer,pfizer,orion,merck,astellas,astrazeneca,janssen
[' enza ', 'propel', ' daro ', 'brca', 'crpc']
fred saad gives a propel trial update by subgroup. major pfs benefit in brca, hrrm and slight benefit in hrr neg. os immature. is the added tox worth it? will this regimen be used (mcrpc, though now all patients should have abi, apa, enza or daro in mhspc)? #esmo22 
Enjoying oncology, without meaning to sound too cynical